YZYi-Feng Zhang

Yi-Feng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Feng Zhang has a total of 188 co-authors. Here are the top co-authors by number of shared publications:

  • Hui-Xiong Xu

    Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China

    9 shared publications
  • Ying Zhang

    Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

    9 shared publications
  • Bo-Ji Liu

    Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound, Research and Education Institute, Clinical Research Center for Interventional Medicine, School of Medicine, Tongji University, Shanghai, China.; Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, Shanghai, China

    5 shared publications
  • Guang Xu

    Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

    5 shared publications
  • Hui-Xiong Xu

    Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, China

    5 shared publications
  • Yun-Yun Liu

    Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound, Research and Education Institute, Clinical Research Center for Interventional Medicine, School of Medicine, Tongji University, Shanghai, China.; Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, Shanghai, China

    5 shared publications

Latest Publications

  • A New Contrast-Enhanced Ultrasound (CEUS) Reporting and Data System for Breast Lesions

    by Jiayi Qiu, Hengqi Zhang, Hui Liu, Xiaolong Li, Hansheng Xia, Lehang Guo, Liping Sun, Huixiong Xu, Yifeng Zhang

  • Intelligent Diagnosis of Follicular Carcinoma Thyroid Cancer with a Novel Deep Learning Model

    by Size Hou, Yunyun Liu, Ming Cai, Jingzhou Xu, Jun Qi, Xiaopan Cai, Qiang Niu, Yifeng Zhang, Huixiong Xu, Jiangang Chen

    Distinguishing follicular thyroid carcinoma (FTC) from follicular adenoma (FTA) preoperatively remains a significant challenge in thyroid nodule management. This study aims to develop and validate a novel, interpretable deep learning model that explicitly leverages the critical diagnostic feature—tumor margins—to address this issue. A total of 577 patients, 435 females and 142 males (mean age, 51.05 \(\pm\) 8.31), were collected from two different centers. A total of 4358 thyroid US images were prospectively collected, with 3140 images from one center randomly divided into the training set and the validation set with a ratio of 4:1 for training the deep learning (DL) model, while 1218 images from the other center were viewed as a test dataset for the evaluation. We propose an end-to-end graph convolutional network that constructs a graph representation from ultrasound image patches, explicitly modeling the structural relationships between features, particularly at the tumor boundary. The model is optimized using a maximum code rate reduction (MCR2) loss to enhance feature discrimination. The overall prediction accuracy and AUC of the independent test set and validation dataset were 90.13%, 82.10%, 92.35%, and 87.36%, respectively, achieving significant and consistent improvement compared to other deep learning baselines. Our proposed model could diagnose FTC with good performance. By successfully incorporating domain knowledge and validating on multicenter data, this study represents a significant step toward reliable AI-assisted diagnosis of thyroid cancer.


  • Open Access

    Deep Learning Based on Automated Breast Volume Scanner Images for the Diagnosis of Breast Lesions: A Multicenter Diagnostic Study

    by Hui Liu, Ying Zhang, Bin Tan, Yi-Fei Yin, Li-Xia Yan, Li-Hua Xiang, Dan-Dan Shan, Yun-Yao Zhang, Shi-Si Ding, Guang Xu, et al.

    Objectives: To develop a deep learning (DL) model for the automated detection and diagnosis of breast cancer utilizing automated breast volume scanner (ABVS) images, and to compare its diagnostic performance with that of radiologists in screening ABVS examinations.


  • Open Access

    Optimizing Thyroid Nodule Management With Artificial Intelligence: Multicenter Retrospective Study on Reducing Unnecessary Fine Needle Aspirations

    by Jia-Hui Ni, Yun-Yun Liu, Chao Chen, Yi-Lei Shi, Xing Zhao, Xiao-Long Li, Bei-Bei Ye, Jing-Liang Hu, Li-Chao Mou, Li-Ping Sun, et al.

    Background: Most artificial intelligence (AI) models for thyroid nodules are designed to screen for malignancy to guide further interventions; however, these models have not yet been fully implemented in clinical practice. Objective: This study aimed to evaluate AI in real clinical settings for identifying potentially benign thyroid nodules initially deemed to be at risk for malignancy by radiologists, reducing unnecessary fine needle aspiration (FNA) and optimizing management. Methods: We retrospectively collected a validation cohort of thyroid nodules that had undergone FNA. These nodules were initially assessed as “suspicious for malignancy” by radiologists based on ultrasound features, following standard clinical practice, which prompted further FNA procedures. Ultrasound images of these nodules were re-evaluated using a deep learning–based AI system, and its diagnostic performance was assessed in terms of correct identification of benign nodules and error identification of malignant nodules. Performance metrics such as sensitivity, specificity, and the area under the receiver operating characteristic curve were calculated. In addition, a separate comparison cohort was retrospectively assembled to compare the AI system’s ability to correctly identify benign thyroid nodules with that of radiologists. Results: The validation cohort comprised 4572 thyroid nodules (benign: n=3134, 68.5%; malignant: n=1438, 31.5%). AI correctly identified 2719 (86.8% among benign nodules) and reduced unnecessary FNAs from 68.5% (3134/4572) to 9.1% (415/4572). However, 123 malignant nodules (8.6% of malignant cases) were mistakenly identified as benign, with the majority of these being of low or intermediate suspicion. In the comparison cohort, AI successfully identified 81.4% (96/118) of benign nodules. It outperformed junior and senior radiologists, who identified only 40% and 55%, respectively. The area under the curve (AUC) for the AI model was 0.88 (95% CI 0.85‐0.91), demonstrating a superior AUC compared with that of the junior radiologists (AUC=0.43, 95% CI 0.36‐0.50; P=.002) and senior radiologists (AUC=0.63, 95% CI 0.55‐0.70; P=.003). Conclusions: Compared with radiologists, AI can better serve as a “goalkeeper” in reducing unnecessary FNAs by identifying benign nodules that are initially assessed as malignant by radiologists. However, active surveillance is still necessary for all these nodules since a very small number of low-aggressiveness malignant nodules may be mistakenly identified.


  • New Thyroid Imaging Reporting and Data System (TIRADS) Based on Ultrasonography Features for Follicular Thyroid Neoplasms: A Multicenter Study

    by Bo-Ji Liu, Yun-Yun Liu, Jing Wan, Ying Zhang, Di Ou, Hong-Feng He, John P. Pineda, Hong Han, Yi-Feng Zhang, Hui-Xiong Xu


  • Open Access

    Can ACR TI-RADS predict the malignant risk of medullary thyroid cancer?

    by Ying Zhang, Bei-Bei Ye, Han-Xiang Wang, Bo-Ji Liu, Yun-Yun Liu, Qing Wei, Chuan Qin, Yi-Feng Zhang


  • Open Access

    Bacteria‐Mediated Tumor‐Targeting Delivery of Multienzyme‐Mimicking Covalent Organic Frameworks Promoting Pyroptosis for Combinatorial Sono‐Catalytic Immunotherapy

    by Yunyun Liu, Lihua Xiang, Yitong Li, Shen Zhang, Ying Zhang, Hui Shi, Hui Liu, Dou Du, Bangguo Zhou, Beibei Ye, et al.

    Pyroptosis, an inflammatory cell death, has attracted great attention for potentiating a strong immune response against tumor cells. However, developing powerful pyroptosis inducers and then activating specific pyroptosis still remains challenging. Herein, a PEG‐CuP‐COF@∆St nanosystem is rationally designed, consisting of PEG‐CuP‐COF nanozyme pyroptosis inducers and tumor‐targeting bacteria of the Salmonella Typhimurium strain VNP20009 (ΔSt), with an affinity for the tumor hypoxic microenvironment. The PEG‐CuP‐COF nanozymes possessed excellent sonodynamic performance and multienzyme‐mimicking activities to generate reactive oxygen species (ROS) and then induce potent pyroptosis. The superoxide dismutase‐ and peroxidase‐mimicking activities of PEG‐CuP‐COF catalytically produced hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals (•OH) which have important value in triggering acute inflammatory responses and pyroptosis. Moreover, PEG‐CuP‐COF showed outstanding glutathione peroxidase‐mimicking activities, impairing the antioxidant defense in tumor cells and enhancing sonodynamic efficiency by making them more vulnerable to ROS‐induced damage. During in vivo studies, PEG‐CuP‐COF@∆St nanosystem with its self‐driven property exhibited impressive tumor‐targeting capability and activated Caspase‐3/gasdermin E‐dependent pyroptosis to inhibit tumor growth. More importantly, it induced a powerful immune memory effect to prevent bone metastasis. In summary, this study introduces an innovative approach for combinatorial sono‐catalytic immunotherapy using bacteria‐mediated tumor‐targeting delivery of nanozymes as specific pyroptosis inducers.


  • Open Access

    A diagnostic protein assay for differentiating follicular thyroid adenoma and carcinoma

    by Yaoting Sun, He Wang, Lu Li, Jianbiao Wang, Wanyuan Chen, Li Peng, Pingping Hu, Jing Yu, Xue Cai, Nan Yao, et al.

    Differentiating follicular thyroid adenoma (FTA) from carcinoma (FTC) remains challenging due to similar histological features separate from invasion. In this study, we aim to develop and validate DNA and protein-based classifiers for FTA/FTC differentiation. We collected 2443 samples from 1568 patients across 24 centers and applied next-generation sequencing, as well as discovery and targeted proteomics. Machine learning models were developed and compared utilizing DNA and/or protein features. The discovery protein-based model (AUC 0.899) outperformed the gene-based model (AUC 0.670). Consequently, we generated a protein-based model with targeted mass spectrometry and further validated it in three independent testing sets. The 24-protein-based model achieved high performance in the retrospective sets (AUC 0.871 and 0.853) and the prospective fine-needle aspiration biopsies (AUC 0.781). The classifier notably illustrated a 95.7% negative predictive value for ruling out malignant nodules. This study offers a promising protein-based approach for differential diagnosis of FTA and FTC. Highlights: Genetic and proteomic profiling of follicular thyroid tumors from 1568 patients across 24 centers AI model based on proteins (AUC 0.899) outperformed that based on gene mutations (AUC 0.670) for differentiation of FTA and FTC Validation of the protein model in two retrospective cohorts (AUCs: 0.871, 0.853) and a prospective (AUC 0.781) The protein model has 95.7% negative predictive value for ruling out malignant nodules


  • Predicting tall-cell subtype of papillary thyroid carcinomas independently with preoperative multimodal ultrasound

    by Bei-Bei Ye, Yun-Yun Liu, Ying Zhang, Bo-Ji Liu, Le-Hang Guo, Qing Wei, Yi-Feng Zhang, Hui-Xiong Xu

    This study aimed to explore the differences between tall-cell subtype of papillary thyroid carcinoma (TCPTC) and classical papillary thyroid carcinoma (cPTC) using multimodal ultrasound, and identify independent risk factors for TCPTC to compensate the deficiency of preoperative cytological and molecular diagnosis on PTC subtypes. Forty-six TCPTC patients and 92 cPTC patients were included. Each patient received grey-scale ultrasound, colour Dopplor flow imaging (CDFI) and shear-wave elastography (SWE) preoperatively. Clinicopathologic information, grey-scale ultrasound features, CDFI features and SWE features of 98 lesions were compared using univariate analysis to find out predictors of TCPTC, based on which, a predictive model was built to differentiate TCPTC from cPTC and validated with 40 patients. Univariate and multivariate analyses identified that extra-thyroidal extension (odds ratio [OR], 15.12; 95% CI, 2.26-115.44), aspect ratio (≥0.91) (OR, 29.34; 95% CI, 1.29-26.23), and maximum diameter ≥14.6 mm (OR, 20.79; 95% CI, 3.87-111.47) were the independent risk factors for TCPTC. Logistic regression equation: P = 1/1+ExpΣ[−5.099 + 3.004 × (if size ≥14.6 mm) + 2.957 × (if aspect ratio ≥ 0.91) + 2.819 × (if extra-thyroidal extension). The prediction model had a good discrimination performance for TCPTC: the area under the receiver-operator-characteristic curve, sensitivity, and specificity were 0.928, 0.848, and 0.954 in cohort 1, and the corresponding values in cohort 2 were 0.943, 0.923, and 0.926, respectively. Ultrasound has the potential for differential diagnosis of TCPTC from cPTC. A prediction model based on ultrasound characteristics (extra-thyroidal extension, aspect ratio ≥0.91, and maximum diameter ≥14.6 mm) was useful in predicting TCPTC. Multimodal ultrasound prediction of TCPTC was a supplement to preoperative cytological diagnosis and molecular diagnosis of PTC subtypes.